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Abstract: 
 
 
 
Background 
Slow progress in improving the outcome of ovarian with chemotherapy over 
the last decade has stimulated research into molecularly targeted therapy. 
PARP inhibitors target DNA repair and are specifically active in cells that have 
impaired repair of DNA by the homologous recombination (HR) pathway. 
Cells with mutated BRCA function have HR deficiency, which is also present 
in a significant proportion of non BRCA-mutated ovarian cancer. 
Design 
In the last decade olaparib, the first and most-investigated oral PARP inhibitor 
has undergone phase I-III trials as a single agent, in comparison to and in 
addition to chemotherapy, and as a maintenance therapy following 
chemotherapy. 
Results 
The greatest benefit to-date has been in the maintenance setting, prolonging 
the progression-free survival of high-grade serous ovarian cancer with a 
BRCA1/2 mutation. In this group of patients olaparib has received approval as 
maintenance following chemotherapy from the EMA, and accelerated 
approval as a single agent in women who have had 3 or more lines of 
therapy. Olaparib can be given for a prolonged period with few significant side 
effects in most patients. Similar trials with other PARP inhibitors (rucaparib, 
niraparib and veliparib) are in progress and include non-BRCA mutated 
ovarian cancer. Second generation studies are exploring the combination of 
PARP inhibitors with ant-angiogenic drugs. 
Conclusions 
PARP inhibitors represent a step change in the management of ovarian 
cancer. BRCA mutations are the first genotypic predictive markers in ovarian 
cancer and can be used to select patients who will most likely benefit from 
PARP inhibitors. BRCA testing is now becoming a routine part of the 
evaluation of women with ovarian cancer and tests for HR deficiency are 
being used to evaluate PARP inhibitors in an extended population of non 
BRCA-mutated ovarian cancer.   
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Introduction: 
 
The introduction of platinum-based drugs and paclitaxel were landmark 
developments in the treatment of ovarian cancer. However, there has been 
little progress in the results of first-line therapy for more than a decade, and 
long-term survival improvements seen during this time have been due to 
better treatment of recurrent disease. Progression-free survival (PFS) in 
‘platinum-sensitive’ relapsed ovarian cancer treated with platinum-
combination therapies has remained relatively unchanged [1], and around 11 
months, but women are being offered a greater number of  lines of treatment. 
During this time maintenance therapy to delay progression and re-treatment 
with chemotherapy has evolved as a new therapeutic approach. Inhibition of 
angiogenesis [2, 3] and DNA repair pathways are two strategies that have led 
this development.  The second is exemplified by inhibitors of PARP (poly ADP 
ribose polymerase) an important enzyme activated in response to single-
strand damage of DNA. It was originally believed that PARP inhibitors could 
be used to potentiate chemotherapy [4], but the observation that the survival 
of cells with homozygous mutations of the BRCA1 or BRCA 2 genes is 
significantly impaired by PARP inhibitors [5, 6] has opened new treatment 
opportunities for ovarian cancer.  Cells with defective BRCA proteins are 
deficient in the repair of double-stranded DNA breaks by homologous 
recombination (HR) and rely on other pathways to repair DNA damage, 
notably the PARP pathway that detects single DNA strand breaks and 
activates a number of effector proteins to initiate repair. Inhibition of PARP in 
the presence of HR deficiency (HRD) leads to cell death from gross genetic 
disarray due to a process called ‘synthetic lethality’ [7]. Several PARP 
inhibitors are being evaluated in ovarian cancer. Initial studies were in BRCA 
deficient tumours but as knowledge of the molecular and genetic biology has 
increased, studies are being extended to include a larger group of ovarian 
tumours. 
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Early clinical trials with PARP inhibitors: 
 
Olaparib, (AZD2281) is a potent small-molecule oral PARP inhibitor and was 
the first to enter clinical trials in ovarian cancer and show clinical activity in 
women with BRCA1 or BRCA2 mutations. Tumour responses were seen 
during the first dose escalation studies and many of these patients who had 
previously been treated with several lines of therapy had durable responses. 
The key side effects seen in some patients were fatigue (30%), nausea (32%) 
and anaemia (5%)[8]. In the 19 patients with a BRCA1/2 mutation (which 
included ovarian, breast and prostate cancer), 63% had a clinical benefit from 
olaparib treatment with radiological or tumour-marker responses, or disease 
stabilisation for a period of 4 months or greater. In an expansion phase in 
ovarian cancer, there was a 40% response-rate[9]. Response-rates were 
associated with the platinum-free interval, with an overall clinical benefit rate 
of 69.2%, 45.8% and 23.1% in the ‘platinum-sensitive’ (defined as recurrence 
six or more months after prior platinum therapy), ‘platinum-resistant’ (defined 
as recurrence less that six months after prior platinum therapy) and ‘platinum-
refractory’ groups respectively. Although responses were seen at 100 mg 
twice daily a multicentre phase II study was undertaken to assess the efficacy 
and safety of oral olaparib monotherapy at the maximum tolerated dose (400 
mg twice daily. Two cohorts of heavily pre-treated patients with a median of 
three previous chemotherapy regimens (range 1-16) and BRCA1/2 mutations 
were enrolled. An objective response was observed in 33% of patients in the 
400 mg twice daily regimen and 13% of the 100 mg twice daily group, with a 
median PFS of 5.8 months (95% CI 2.8-10.6) and 1.9 months (95% CI 1.8-
3.6) respectively [10]. 
 
 
Strategies to develop Olaparib in Ovarian Cancer: 
 
The initial development pathway compared the activity of olaparib with 
pegylated liposomal doxorubicin (PLD) in BRCA-mutated ovarian cancer. The 
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first multicentre, open-label phase randomised II trial included both a 200 mg 
bd dose of olaparib and the later established phase II dose of 400 mg bd. In 
‘study 12’, 97 patients with ovarian cancer that recurred within 12 months of 
prior platinum therapy and with a confirmed germline BRCA1 or BRCA2 
mutation were randomised to one of two doses of olaparib given continuously, 
or intravenous PLD, 50 mg/m2 every 28 days. The median PFS was 6.5 
months (95% CI, 5.5 to 10.1 months), 8.8 months (95% CI, 5.4 to 9.2 
months), and 7.1 months (95% CI, 3.7 to 10.7 months) for the olaparib 200 
mg, olaparib 400 mg, and PLD groups, respectively, with no statistically 
significant difference in PFS (hazard ratio (HR), 0.88; 95% CI, 0.51 to 1.56; p 
= 0.66) for the combined olaparib doses versus PLD [11]. The overall 
response rates by RECIST were also not significantly different (25%, 31%, 
and 18% for olaparib 200 mg, olaparib 400 mg, and PLD, respectively). Whilst 
the activity of olaparib was as anticipated from the phase I/II trials, the 
response to PLD in patients with a BRCA1/2 mutation was greater than 
expected. Subsequent retrospective data have confirmed that patients with 
recurrent ovarian cancer and a BRCA1/2 mutation respond well to PLD [12], a 
drug that causes DNA damage that is less well repaired in tumours with HRD. 
 
During this time, other phase II studies were performed that included women 
with recurrent ovarian cancer without a BRCA mutation. Emerging data from 
The Cancer Genome Atlas study suggested that HRD could be more 
widespread in ovarian cancer, particularly in high-grade serous tumours that 
are sensitive to platinum-based treatments [13]. A phase II study in recurrent 
ovarian cancer confirmed this; 11 out of 46 patients  (24%; 14–38) without a 
BRCA mutation responded to olaparib[14].  
 
Maintenance therapy  
 
The concept of evaluating olaparib as a maintenance therapy to extend PFS 
in recurrent ovarian cancer arose from the aforementioned data. A 
randomised trial, ‘study 19’ was launched in 2008 to measure the PFS 
following the addition of olaparib or placebo maintenance therapy following 
the completion of platinum-based chemotherapy for platinum-sensitive high 
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grade serous relapsed ovarian, fallopian tube or peritoneal cancer. A 
minimum of two prior platinum containing regimens was required for study 
entry, and the median number of regimens received in both arms was three.  
In the 265 randomised patients BRCA status was known in 38%. The primary 
endpoint was PFS, which was significantly increased by olaparib, 400 mg bd 
[HR 0.35; 95% CI, 0.25–0.49; p<0.00001], extending the median time to 
progression or death following chemotherapy by 3.6 months (from 4.8 to 8.4 
months)[15]. An early evaluation of overall survival (at 38% maturity) showed 
no difference, and this led to a temporary cessation of the development of 
olaparib, as it was felt unlikely that it would be approved by regulatory 
authorities. However, in a pre-planned subgroup analysis it appeared that 
there might be a survival benefit in the subgroup with a known BRCA 
mutation.  As a consequence, a retrospective analysis of BRCA status in 
germline and/or tumour was performed as consent had been obtained at the 
outset of the trial. The germline BRCA and tumour BRCA status became 
available in 96% of the patients and 136 (51.3%) had a BRCA mutation in 
either germline or tumour (BRCAm) and 118 were BRCA wild-type. Re-
analysis showed that the effect of olaparib in BRCAm patients was even 
greater. The median PFS was extended by 6.9 months, from 4.3 to 11.2 
months [HR=0.18; 95% CI (0.10, 0.31); P<0.00001] [16]. A smaller but 
significant benefit was also seen in BRCA wild-type patients [HR=0.54; 95% 
CI (0.34, 0.85); P=0.0075].  There was no significant difference in overall 
survival at the second interim analysis (58% maturity). For the whole group 
the hazard ration was 0.88 (95% CI 0·64–1·21; p=0·44); similar findings were 
noted for patients with BRCAm (HR 0·73 [0·45–1·17]; p=0·19). However, the 
detection of differences in survival is confounded by crossover to a PARP 
inhibitor at a later date in 23% of patients taking placebo. The study confirmed 
that olaparib is well tolerated by most patients with fatigue, nausea and 
anaemia accounting for the greatest differences in side-effects compared to 
placebo. Dose interruptions due to side-effects occurred in 36% of those 
taking olaparib compared to 16% of patients on placebo. Similarly, dose 
reductions were more common in women taking olaparib than placebo, 42% 
versus 22 %, respectively. Nine patients taking olaparib discontinued 
treatment due to adverse events compared with 2 in the placebo group. 
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It is well known that even large differences in PFS do not often result in 
significant differences in OS due to the effect of post-progression therapies 
and crossover. Consequently, the European Medicines Agency (EMA) 
proposed that the time to subsequent progression after next-line therapy, 
(PFS2) could be accepted as a secondary supportive regulatory endpoint to 
PFS [17]. Measurement of PFS is an important scientific and regulatory 
endpoint but its practical clinical value is open to question. For patients, it is 
not so much the time to progression, but rather the time to the next line of 
treatment that is clinically important. Patients may not necessarily start a new 
line of treatment merely because of RECIST progression. Such decisions in 
ovarian cancer are usually based on composite information of the radiological 
appearances of the tumour, symptoms and the CA-125 level. In ‘study 19’ 
unblinding of the treatment allocation did not occur on progression. Many 
patients did not immediately restart chemotherapy on progression and some 
continued trial treatment beyond RECIST progression until the start of the 
next line of treatment. An exploratory analysis of TFST (Time to First 
Subsequent Therapy) and TSST (Time to Second Subsequent Therapy), an 
approximation of PFS2 was performed to evaluate these secondary 
endpoints. In the overall population, the time to initiation of further treatment 
was significantly longer in the olaparib group than with placebo (13.4 months 
versus 6.7 months, HR 0.40; 95% CI 0.30-0.52) and in both the BRCAm 
population (15.6 months versus 6.5 months, HR 0.33; 95% CI 0.22-0.50) and 
wild-type BRCA subgroups (12.9 months versus 6.9 months, HR 0.45; 95% CI 
0.30-0.67) [16]. Olaparib also extended the time to second subsequent 
therapy in both BRCA1/2 mutated and BRCA1/2 wild-type tumours suggesting 
that olaparib treatment did adversely affect a response to subsequent 
treatment. 
 
The results of the BRCAm subgroup analysis were submitted to the EMA and 
approval for maintenance olaparib was granted in October 2014. A 
submission to the USA Food and Drug Administration (FDA) was rejected but 
in December 2014, accelerated approval to use olaparib as a single agent in 
patients with a germline BRCA mutation who have had at least 3 prior lines of 
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therapy was granted by the FDA. This was based on composite data from 
several studies, but principally, ‘study 42’ a trial of olaparib monotherapy that 
included 193 patients with ovarian cancer with a BRCA1/2 mutation [18]. The 
data reviewed by the FDA were in 137 women who had received three or 
more previous lines of therapy. In this group, 34% of women had responded 
to olaparib for an average of 7.9 months.  Thus, on two sides of the Atlantic 
there are very different indications for the same drug, both at 400 mg bd. 
Following this, a confirmatory trial in a population with a prospectively 
determined BRCAm population, including high grade serous and endometrioid 
tumours was launched using a tablet preparation of olaparib 300 mg bd (4 
tablets per day), rather than the rather impractical 16 capsules a day needed 
for the 400 mg bd dose. The tablet formulation of 300mg bd has been shown 
to have similar bioavailability. This trial, SOLO2 (NCT01874353) has 
completed accrual but results are not yet available. 
 
The studies to-date have clearly demonstrated that olaparib is a clinically 
valuable new therapy for women with BRCAm ovarian cancer, and that for the 
first time, there is a therapy for this disease defined by a genetically predictive 
biomarker. The implications for this are far-reaching as testing for BRCA 
mutations needs to be incorporated into clinical practice. It is estimated that 
up to 20% of women with high-grade serous ovarian cancer have a germline 
or somatic BRCA mutation [19] and many of these women do not have a 
family history of cancer [20]. Strategies for introducing routine BRCA mutation 
testing are being incorporated by individual countries. Their implementation 
can be complex; the cost of testing, involvement of local genetics units and 
social implications of identifying germline mutations all need to be taken into 
consideration. Furthermore, testing only for germline BRCA mutations will 
miss somatic mutations that may be present in 5-6% of these tumours [21, 
22]. 
 
Development strategies of PARP inhibitors in ovarian cancer: 
 
The promising results seen with the early studies using olaparib, and 
temporary cessation of the development of olaparib announced in December 
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2011 led other manufactures of PARP inhibitors to develop similar a 
maintenance programme (TABLE 1). Both niraparib and rucaparib have been 
shown to be active in patients with a BRCA1/2 mutation [23, 24]. Both 
maintenance studies are including patients without a BRCAm, to test the 
effect of PARP inhibitors in the BRCA wild-type population, incorporating a 
companion diagnostic test for HRD. The SOLO1 trial with olaparib tablets has 
a similar design to SOLO2 but is evaluating the role of olaparib maintenance 
in the first-line setting. There continues to be interest in combining PARP 
inhibitors with chemotherapy. Although olaparib combined with carboplatin 
and paclitaxel for platinum-sensitive recurrent disease increased PFS over 
chemotherapy alone, the results did not suggest an additive effect of olaparib 
and chemotherapy; the dose and schedule of both carboplatin and olaparib 
had to be altered to reduce toxicity [25]. However, veliparib in combination 
with carboplatin and paclitaxel is being evaluated in a three-arm trial (GOG 
3005), comparing veliparib with chemotherapy, and also as maintenance in 
the first line treatment of ovarian cancer. In 2015 rucaparib was given 
‘breakthrough’ status by the FDA and it is likely that some if not all the other 
PARP inhibitors will be licensed in the future. Whilst a choice of drug may 
exist, there are still many key unanswered questions, such as: when in the 
treatment pathway should PARP inhibitors be used? Are they best used as 
maintenance treatment after chemotherapy, or as monotherapy for active 
disease? What are the mechanisms responsible for resistance, and can 
patients be re-treated with the same or a different PARP inhibitor later in the 
treatment pathway?  
 
‘Second generation’ molecular combination therapy studies: 
 
It has been hypothesised that there may be synergy between PARP inhibitors 
and other signalling pathways inhibitors with little overlapping toxicity. Pre-
clinical studies have demonstrated the additive effect of anti-angiogenesis and 
PARP inhibition as hypoxia leads to down regulation of HR repair proteins and 
enhanced PARP inhibitor sensitivity [26, 27]. A phase I trial combining the oral 
VEGF receptor tyrosine kinase inhibitor, cediranib with olaparib demonstrated 
activity in recurrent ovarian cancer with an objective response rate of 44% 
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[28] leading to a randomised phase II study that was recently reported. Liu 
and colleagues randomised patients with relapsed high-grade serous or 
endometrioid ovarian cancers to olaparib (400mg capsules twice-daily, n=46) 
monotherapy, or the combination of olaparib and cediranib (cediranib 30 mg 
daily and olaparib 200 mg twice daily, n=44). BRCA1/2 mutations were 
present in 52% of patients in both treatment arms. The median PFS was 
significantly longer in the combination arm than for olaparib alone, 17.7 
months versus 9.0 months, (HR 0.42; 95% CI 0.23–0.76; p=0.005), and the 
objective response rate higher, 79.6% versus 47.8%, (odds ratio 4.24, 95% CI 
1.53-12.22;p=0.002) [29]. An exploratory analysis was performed in BRCA 
mutation and BRCA wild-type or unknown subsets which showed that the 
relative benefit appeared greater in patients in the BRCA1/2 wild-
type/unknown group, median PFS 16.5 months versus 5.7 months in the 
BRCA mutated group (HR 0.32 95%CI 0.14 -0.74). This retrospective analysis 
should be interpreted with caution as the number of patients in each subset 
was small. These results suggest that the combination of olaparib and 
cediranib could be synergistic and the results have led to the launch of new 
studies combining olaparib with cediranib, or other anti-angiogenic agents, 
and trials with other PARP inhibitors and anti-angiogenic agents (TABLE 2). 
 
 
Summary: 
 
PARP inhibitors are a new group of drugs for the treatment of ovarian cancer. 
Olaparib is the first-in-class to be licensed for the treatment of recurrent 
ovarian cancer harbouring deleterious BRCA mutations. These constitute the 
first predictive markers for the treatment of ovarian cancer. Two different 
indications for use in the USA and Europe underline the complexity of clinical 
trial approvals, but also the versatility of this type of drug. Several other PARP 
inhibitors are undergoing clinical trials in the maintenance setting, in 
combination with chemotherapy, and with other molecular targeted therapies. 
Results are expected during the next two to five years and will most likely 
extend the opportunities for treatment of ovarian cancer. Testing for BRCA 
mutations now needs to be incorporated into everyday clinical practice so that 
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patients have the opportunity of benefiting from this new personalised 
therapy. 
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TABLE 1 
 
Multi-centre trials intended to expand the licensing of PARP inhibitors in 
ovarian cancer 
 
PARP Inhibitor Company Target Summary 
Olaparib 
(AZD2281) 
AstraZeneca PARP1/2/3 Phase III trials with tablet formulation 
- 1st line (SOLO-1; NCT01844986) in 
BRCAm patients;  
- Relapsed platinum-sensitive high 
grade serous and endometrioid 
tumours in BRCAm patients (SOLO-2; 
NCT01874353) 
Rucaparib  
(AG-014699; 
CO-338) 
Clovis 
Oncology 
PARP1/2 Ongoing phase II studies in platinum-
sensitive disease in conjunction with a 
companion diagnostic test for HRD 
(ARIEL2; NCT01891344) 
 
Randomised maintenance study in 
platinum sensitive recurrent high grade 
ovarian cancer in both BRCAm, BRCA 
wild-type patients (ARIEL3; 
NCT01968213)  
 
Veliparib (ABT-
888) 
Abbvie PARP1/2 First-line 3–arm phase III in combination 
with carboplatin and paclitaxel, and one 
arm continuing veliparib maintenance 
therapy (GOG 3005; NCT02470585)  
Niraparib 
(MK4827) 
Tesaro PARP1/2 Ongoing phase III (NOVA; NCT01847274) 
maintenance in BRCAm and BRCA wild-
type; companion diagnostic for HRD being 
developed for wild type patients 
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TABLE 2 
Phase III clinical trials combining anti-angiogenic drugs with PARP inhibitors 
 
PARP 
inhibitor 
NCT Trial 
Number  
Anti-angiogenic 
agent 
Combination 
Platinum Status 
Inclusion 
Criteria 
Olaparib 
PAOLA-1 
(NCT02477644) 
Bevacizumab Olaparib or placebo in 
combination with platinum-taxane 
and bevacizumab and as 
maintenance therapy  
First line treatment  
HGOC 
stage IIIB-IV 
Olaparib 
NRG-GY004  
NCI-2015-00606 
(NCT02446600) 
cediranib 
Olaparib and cediranib or 
Platinum- doublet chemotherapy  
Platinum-sensitive  
HGOC or 
gBRCA and 
any high-
grade 
histology 
Olaparib 
NRG-GY005  
NCI-2015-00651 
(NCT02502266) 
cediranib 
Olaparib and cediranib or 
chemotherapy 
Platinum-resistant  
HGOG or 
gBRCA and 
any high-
grade 
histology 
Olaparib ICON 9 
cediranib Olaparib with cediranib versus 
cediranib and placebo as 
maintenance therapy following 
platinum-based chemotherapy 
with cediranib 
Platinum-sensitive HGOC 
Niraparib 
AVANOVA 
(NCT02354131) 
Bevacizumab Three-arm study comparing 
niraparib, bevacizumab and 
niraparib-bevacizumab 
combination 
Platinum-sensitive HGOC 
HGOG= High-grade serous or endometrioid
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